Skip to main
ABBV
ABBV logo

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie (ABBV) Analyst Ratings

Based on 36 analyst ratings
Buy
Strong Buy 28%
Buy 42%
Hold 28%
Sell 0%
Strong Sell 3%

Bulls say

AbbVie has reaffirmed its guidance for a high single-digit sales compound annual growth rate (CAGR) from 2024 to 2029, signaling robust growth potential driven primarily by its strong immunology products, Skyrizi and Rinvoq, with anticipated sales exceeding $20 billion and $11 billion, respectively, by 2027. The company's fourth-quarter 2024 results exceeded expectations, with sales reaching $15.1 billion, highlighting the performance of its key immunology offerings. Despite a softened outlook for its Aesthetics franchise, AbbVie's adjusted long-term revenue projections and initial earnings per share guidance for 2025 demonstrate a solid foundation for sustainable growth moving forward.

Bears say

AbbVie faces several significant risks that contribute to a negative outlook on its stock. The company is grappling with disappointing sales performance in its key products, such as Humira and its aesthetic offerings, while experiencing competitive pressures in both its immunology and oncology segments. Furthermore, ongoing macroeconomic challenges, potential regulatory setbacks, and heightened risks in the clinical development pipeline may hinder the company's ability to achieve its long-term growth expectations.

AbbVie (ABBV) has been analyzed by 36 analysts, with a consensus rating of Buy. 28% of analysts recommend a Strong Buy, 42% recommend Buy, 28% suggest Holding, 0% advise Selling, and 3% predict a Strong Sell.

This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AbbVie (ABBV) Forecast

Analysts have given AbbVie (ABBV) a Buy based on their latest research and market trends.

According to 36 analysts, AbbVie (ABBV) has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $177.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $177.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AbbVie (ABBV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.